1.05

0.00% 0.01

Tscan Therapeutics Inc (TCRX)

Overview News Price History Financials Discussions Forecast

Tscan Therapeutics Inc stock is traded at $1.05, with a volume of 327.34K. It is up +0.00% in the last 24 hours and down -6.31% over the past month. TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Previous Close:

$1.04

Open:

$1.06

24h Volume:

327.34K

Relative Volume:

0.40

Market Cap:

$59.30M

Revenue:

$21.05M

Net Income/Loss:

$-89.22M

P/E Ratio:

-0.5866

EPS:

-1.79

Net Cash Flow:

$-64.50M

1W Performance:

+16.11%

1M Performance:

-6.31%

6M Performance:

-29.73%

1Y Performance:

-66.56%

1-Day Range:

$0.9821

$1.0699

1-Week Range:

$0.8901

$1.07

52-Week Range:

$0.8824

$3.21

Tscan Therapeutics Inc Stock (TCRX) Company Profile

Name

Tscan Therapeutics Inc

Sector

Healthcare (1135)

Industry

Biotechnology (631)

Phone

857-399-9500

Address

830 WINTER STREET, WALTHAM

Employee

148

Twitter

Next Earnings Date

2025-03-05

Latest SEC Filings

TCRX's Discussions on Twitter

Compare TCRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TCRX Tscan Therapeutics Inc	1.045	59.02M	21.05M	-89.22M	-64.50M	-1.79
VRTX Vertex Pharmaceuticals Inc	461.40	117.47B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	779.72	82.37B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	399.22	52.94B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	847.39	52.33B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	178.08	37.84B	447.02M	-1.18B	-906.14M	-6.1812

Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-16-24	Initiated	BTIG Research	Buy
May-13-24	Initiated	Needham	Buy
Jun-22-23	Initiated	Wedbush	Outperform

Tscan Therapeutics Inc Stock (TCRX) Latest News

Dec 25, 2025

Weekly Recap: Will West Fraser Timber Co Ltd stock see PE expansionTrade Volume Report & Growth-Oriented Investment Plans - moha.gov.vn

Dec 25, 2025

Dec 23, 2025

TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Lynx1 Capital Management Lp Acquires 80,069 Shares - MarketBeat

Dec 23, 2025

TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Buys 75,500 Shares - MarketBeat

Dec 23, 2025

Dec 20, 2025

How TScan Therapeutics Inc. stock reacts to oil pricesTrade Risk Assessment & AI Forecasted Entry/Exit Points - Улправда

Dec 20, 2025

Dec 19, 2025

Why TScan Therapeutics Inc. stock is a must watch in 20252025 Top Decliners & Low Risk Entry Point Guides - Bölüm Sonu Canavarı

Dec 19, 2025

Is TScan Therapeutics Inc. stock safe for conservative investorsJuly 2025 Sector Moves & Stepwise Trade Signal Implementation - DonanımHaber

Dec 19, 2025

Will TScan Therapeutics Inc. stock see PE expansionEarnings Miss & Community Consensus Stock Picks - DonanımHaber

Dec 19, 2025

Is TScan Therapeutics Inc. stock dividend yield sustainable2025 Market Sentiment & Smart Investment Allocation Insights - Улправда

Dec 19, 2025

Dec 09, 2025

Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event By Investing.com - Investing.com South Africa

Dec 09, 2025

Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event - Investing.com Canada

Dec 09, 2025

TCRX: TSC-101 shows durable efficacy and safety, with pivotal trial and market expansion set for next year - TradingView

Dec 08, 2025

Dec 06, 2025

Investor MeetingKey Opinion Leader - marketscreener.com

Dec 06, 2025

TScan Therapeutics Reports Promising Two-Year Relapse-Free Survival Data for TSC-101 in Phase 1 Trial for Hematologic Malignancies - Quiver Quantitative

Dec 06, 2025

TScan Therapeutics Announces Positive Updated Data from the - GlobeNewswire

Dec 06, 2025

How Low Can TScan Therapeutics Stock Really Go? - Trefis

Dec 06, 2025

TScan Therapeutics (TCRX) Price Target Increased by 10.53% to 7.14 - Nasdaq

Dec 06, 2025

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Analysts - MarketBeat

Dec 06, 2025

Dec 05, 2025

Is TScan Therapeutics Stock Built to Withstand a Pullback? - Trefis

Dec 05, 2025

Dec 04, 2025

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - KamloopsBCNow

Dec 04, 2025

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (2025-12-04) - Seeking Alpha

Dec 04, 2025

TScan to host KOL event discussing updated ALLOHA trial data By Investing.com - Investing.com Canada

Dec 04, 2025

TScan Therapeutics To Provide Update On Phase 1 Trial Of TSC-101 In Heme Malignancies Next Week - Nasdaq

Dec 04, 2025

Dec 03, 2025

TScan to host KOL event discussing updated ALLOHA trial data - Investing.com India

Dec 03, 2025

TScan Therapeutics to Host Virtual KOL Event on ALLOHA™ Phase 1 Trial Data and Market Opportunities - Quiver Quantitative

Dec 03, 2025

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities - The Manila Times

Dec 03, 2025

Nov 29, 2025